Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
Status:
Terminated
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The objective is to assess the efficacy and safety of masitinib at 7.5 mg/kg/day in the
treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying
a mutation in the juxta membrane domain of c-Kit and who have not previously been treated for
melanoma.